STEMTECH CORPORATION Stock Price, News & Analysis

Stemtech Corporation (OTCQB: STEK) has announced a series of Business Academies for Independent Business Partners (IBPs) in 2023, scheduled in Mexico, the United States, and Taiwan. The first event will occur in Agua Calientes, Mexico from May 4-6, followed by a gathering in Las Vegas, NV in June, and concluding in Taiwan in October. These academies, part of the Stemtech 360 program, focus on training and promoting new products, including the recent introduction of Cellect One Rapid Renew Stem Cell Peptide Night Cream. This initiative aims to enhance IBPs' financial opportunities and is expected to support business growth globally.

Stemtech Corporation (OTCQB:STEK) has launched two new products in Taiwan as part of its Stemtech 360 program: Cellect One™ Skin Tightening and Repairing Serum and OraStem^® Toothpaste. These additions aim to enhance their existing product offerings and are designed specifically for the Asian market. The company anticipates that these products will drive greater monthly sales than their peak in December 2022. Additionally, Stemtech Taiwan was recognized by the Taiwanese government for ethical business practices. Stemtech focuses on stem cell nutrition and offers income-earning opportunities for its Independent Business Partners.

Stemtech Corporation (OTCQB: STEK) has initiated the registration process for its products as part of its expansion into Colombia, aiming to establish an office in Bogotá. This decision follows requests from Field leaders during a Leadership Event in December 2022 and aligns with the company's 'Just One More' concept. CEO Charles S. Arnold highlighted Colombia's potential market for their stemceutical™ products, particularly emphasizing the new Cellect One™ Rapid Renew Stem Cell Peptide Night Cream. The initiative is part of the 2023 strategic business plan, focusing on growth in Latin America, leveraging advancements in their AdvanceOffice mobile app for better communication and recruitment.

Stemtech Corporation (OTCQB:STEK) announced the appointment of Claude Ayache as Vice President of Finance for its US subsidiary. He will also continue his responsibilities with Stemtech Canada until relocating to Florida. Ayache's expanded role will include strategic collaboration with the executive team and managing financial reporting. His expertise has already contributed to the company's improved regulatory reporting and the acquisition of Life Factor Research. Stemtech has risen to 11th place in the rankings of the top network marketing companies in business momentum, reflecting its growth strategy and investment in infrastructure.

Stemtech Corporation (OTCQB: STEK) has achieved a remarkable rise in its ranking, moving from 159th to 11th in the Business For Home 'Momentum' category, demonstrating significant growth in the network marketing industry. This leap validates Stemtech's strategic efforts, including the launch of their Stemtech AdvanceOffice mobile app and the introduction of the CellectOne™ Rapid Renew Stem Cell Peptide Night Cream. CEO Charles S. Arnold emphasized that this achievement reflects the company's ongoing upward trend, supported by its Independent Business Partners' enthusiasm and new product development initiatives set forth in their VISION 2023 strategy.

Stemtech Corporation (OTCQB:STEK) announced its VISION 2023 strategy, highlighting significant growth in 2022. Key achievements include a 20% increase in new Independent Business Partners and customers. The launch of the AdvanceOffice Mobile app aims to enhance distributor efficiency and communication. New product introductions, particularly the CellectOne™ peptide night cream, are anticipated to drive customer base and revenue growth in 2023. The company plans to host more in-person events to bolster the distributor network and leverage the excitement generated from recent conferences.

Stemtech Corporation (OTCQB: STEK) has announced the launch of an enhanced version of its AdvanceOffice mobile app. This upgrade allows Independent Business Partners (IBPs) to access key performance indicators (KPIs) through integration with Exigo CRM software. The app aims to streamline business operations for IBPs, providing powerful tools for communication and analytics. This development follows a series of strategic improvements and product launches aimed at enhancing the company's direct sales model.

Stemtech Corporation (OTCQB: STEK) announced the appointment of Margie and Mike Mares to its Field Advisory Board. The Mares, who quickly progressed to Diamond Director within six months of joining in July 2021, bring extensive experience in network marketing. Stemtech aims for enhanced transparency and collaboration between its corporate and field teams. The company, recognized for its stemceutical products, continues to innovate and expand its offerings, including the recent launch of the CellectOne™ Rapid Renew Stem Cell Peptide Night Cream.